GoPro, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that GoPro, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $651.54M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $801.47M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $1.01B | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $1.09B | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $1.16B | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | $891.93M | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $1.19B | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $1.15B | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $1.18B | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $1.19B | Feb 15, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $219.17M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $271.30M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $323.57M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $406.83M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $477.11M | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | $314.51M | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $412.79M | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $361.43M | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $384.53M | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $461.92M | Feb 15, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($93.49M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($432.31M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | ($53.18M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $28.85M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $371.17M | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | ($66.78M) | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | ($14.64M) | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | ($109.03M) | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | ($182.87M) | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | ($419.00M) | Feb 15, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($83.34M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($135.03M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | ($75.46M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $38.96M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $113.22M | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | ($36.82M) | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | ($2.33M) | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | ($93.96M) | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | ($163.46M) | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | ($372.97M) | Feb 15, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $126.80M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $185.90M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $165.69M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $139.89M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $141.49M | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | $131.59M | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $142.89M | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $167.30M | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $229.27M | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $358.90M | Feb 15, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($20.67M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($125.14M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | ($32.86M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $5.75M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $229.15M | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | $93.78M | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | ($24.44M) | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | ($42.43M) | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | ($36.85M) | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | ($107.75M) | Feb 15, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.36M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $4.04M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $1.52M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $3.45M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $5.55M | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | $4.88M | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $8.35M | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $11.00M | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $24.06M | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $43.63M | Feb 15, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $427.98M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $543.68M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $967.95M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $1.08B | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | $1.26B | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | $771.40M | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | $792.80M | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $698.36M | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | $850.25M | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | $922.64M | Feb 16, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $351.43M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $391.99M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $412.11M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $465.37M | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | $643.97M | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | $555.38M | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | $559.27M | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $486.25M | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | $551.54M | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | $475.70M | Feb 16, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $76.55M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $151.69M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $555.85M | Mar 12, 2026 |
| FY2025 | Dec 31, 2022 | $611.56M | Mar 12, 2026 |
| FY2024 | Dec 31, 2021 | $615.91M | Mar 17, 2025 |
| FY2023 | Dec 31, 2020 | $216.02M | Feb 9, 2024 |
| FY2022 | Dec 31, 2019 | $233.53M | Feb 10, 2023 |
| FY2021 | Dec 31, 2018 | $212.11M | Feb 11, 2022 |
| FY2020 | Dec 31, 2017 | $298.71M | Feb 12, 2021 |
| FY2019 | Dec 31, 2016 | $446.95M | Feb 14, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $133.75M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $152.35M | Mar 12, 2026 |
| FY2025 | Feb 27, 2024 | $5.90M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $146.46M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $146.46M | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | $146.46M | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | $146.46M | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | $146.46M | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $146.46M | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | $146.46M | Feb 15, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($775.09M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($681.61M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($249.30M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($196.11M) | Feb 9, 2024 |
| FY2023 | Jan 1, 2022 | $47.10M | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | ($279.35M) | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | ($650.52M) | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | ($583.73M) | Feb 12, 2021 |
| FY2019 | Jan 1, 2019 | ($569.09M) | Feb 14, 2020 |
| FY2019 | Dec 31, 2018 | ($569.03M) | Feb 14, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $49.67M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $102.81M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $222.71M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $223.74M | Mar 17, 2025 |
| FY2022 | Dec 31, 2021 | $401.09M | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | $325.65M | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | $150.30M | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $152.10M | Feb 14, 2020 |
| FY2019 | Dec 31, 2017 | $202.50M | Feb 14, 2020 |
| FY2019 | Dec 31, 2016 | $192.11M | Feb 14, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $44.32M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $92.62M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $141.02M | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | $111.29M | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | $218.17M | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | $148.81M | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $138.99M | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | $130.05M | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | $0 | Feb 16, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (2) | Mar 17, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Mar 17, 2025 |
| FY2024 | Dec 31, 2022 | 0 | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Feb 11, 2022 |
| FY2017 | Dec 31, 2017 | (1) | Feb 16, 2018 |
| FY2017 | Dec 31, 2016 | (3) | Feb 16, 2018 |
| FY2017 | Dec 31, 2015 | 0 | Feb 16, 2018 |
| FY2016 | Dec 31, 2014 | 1 | Feb 16, 2017 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Feb 11, 2022 |
| FY2017 | Dec 31, 2017 | (1) | Feb 16, 2018 |
| FY2017 | Dec 31, 2016 | (3) | Feb 16, 2018 |
| FY2017 | Dec 31, 2015 | 0 | Feb 16, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2013 | 81.42M | Feb 20, 2015 |